Navigation Links
Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
Date:6/10/2008

MONTREAL, June 10 /PRNewswire/ - Aegera Therapeutics Inc. is extremely pleased to announce the initiation of a Phase 1 clinical trial of the IAP ("Inhibitor of Apoptosis Protein") inhibitor, HGS1029 (formerly AEG40826), as a monotherapy in patients with advanced solid tumors. This small molecule IAP inhibitor was developed by Aegera and licensed to Human Genome Sciences, Inc. (Nasdaq: HGSI) for oncology development in December 2007. As part of this agreement, Aegera maintains full ownership of all rights to this class of molecules for the Japanese market and global rights for non-oncology indications.

"We are impressed with the research and development teams that HGS has applied to the advancement of this exciting collaborative oncology program. In a very short period of time, their clinical team has advanced this program to its first clinical trial and we are confident that their pro-active approach will lead to the rapid and successful development of this potent molecule across a broad range of cancer indications. In addition, our respective research teams are working very closely together to continue to build on Aegera's IAP expertise and to identify additional back-up and best-in-class compounds to follow the initial lead." commented Dr. Mike Berendt, Aegera President & CEO.

Aegera also announced today the receipt of its first milestone payment under this collaboration agreement. The payment, in the amount of US$5 million, was triggered by the FDA clearance of the Investigational New Drug (IND) application for HGS1029.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing drugs that control apoptosis to address major unmet medical needs. In additi
'/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Aegera Therapeutics welcomes two experienced executives to its board of directors
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
4. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Arana Therapeutics Ltd.
5. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
6. Loic Maurel Joins Exonhit Therapeutics to Become CEO
7. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
8. CV Therapeutics Announces Presentations at the American Diabetes Association 68th Scientific Sessions
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Takedas Antibody Therapeutics Research Company, Takeda San Francisco, Inc. Appoints Mary Haak-Frendscho, Ph.D. as President and CSO
11. Bharatt Chowrira Joins Nektar Therapeutics as Chief Operating Officer and Head of PEGylation Business Unit

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...ire-FirstCall/ -- WaferGen Biosystems, Inc. (OTC B...-of-the-art genetic analysis systems, today announ...ompany,s Scientific Advisory Board. His career ha...vel molecular diagnostics for cancer detection and...putational biology systems for several biotechnolo...
(Date:11/5/2009)...y and vision correction experts listed in the Trus...d at the recently concluded American Academy of Op...isco, California. Dr. Stephen Brint, MD, Dr. Frede...r. Peter Rapoza, MD, Dr. Michael Raizman, MD, Dr. ...dward Manche, MD, and Dr. Parag Majmudar, MD, all ...
(Date:11/4/2009)...wire/ -- DIATHERIX Laboratories, Inc. (DIATHERIX) ...chigan Security Network Homeland Security Market L...maud, Chairman and Chief Executive Officer of DIAT...ced molecular diagnostic testing on bio-preparedne...s and military efforts. ,, "This conference is...
(Date:11/4/2009)...wswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: ...he third quarter ended September 30, 2009. ,, ...improved to $31.0 million or $0.33 per share, as c...r share in the third quarter of 2008. ,, Nek...g efficiencies as compared to a year ago. Total o...
Breaking Biology Technology:WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 2WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 3WaferGen Names Christopher Sears, Ph.D., Architect of High-Value Molecular Diagnostics and Computational Biology Platforms, to Company's Scientific Advisory Board 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9DIATHERIX Laboratories Presents at Homeland Security Conference 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 2Nektar Therapeutics Reports Third Quarter 2009 Financial Results 3Nektar Therapeutics Reports Third Quarter 2009 Financial Results 4Nektar Therapeutics Reports Third Quarter 2009 Financial Results 5Nektar Therapeutics Reports Third Quarter 2009 Financial Results 6Nektar Therapeutics Reports Third Quarter 2009 Financial Results 7Nektar Therapeutics Reports Third Quarter 2009 Financial Results 8Nektar Therapeutics Reports Third Quarter 2009 Financial Results 9Nektar Therapeutics Reports Third Quarter 2009 Financial Results 10
...n. 24 Cardica, Inc.,(Nasdaq: CRDC ) today report...s fiscal 2008 second quarter and six months ended ...t commercial progress, with over 1,000,C-Port syst..., an expanding,product line designed to enable min...vancement for our development-stage products," sai...
...argest Chemically Defined Structure Synthesized,in...p Process to Create Synthetic,Organism, ROCKVILLE... Craig Venter Institute (JCVI) has created the lar...sembling the 582,970 base pair,genome of a bacteri...lished,online today in the journal Science by Dan ...
...ers to Treat More Patients, SUNNYVALE, Calif., Ja...obal leader in the field of radiosurgery,announced...tment planning,service to new and existing CyberKn...e centers to access a dedicated team of remote sci...eatment planning, thereby giving,each center the f...
Other Biology Technology:Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 2Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 3Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 4Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 5Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 6Cardica Announces Fiscal 2008 Second Quarter Financial Results and Business Progress 7Venter Institute Scientists Create First Synthetic Bacterial Genome 2Venter Institute Scientists Create First Synthetic Bacterial Genome 3Venter Institute Scientists Create First Synthetic Bacterial Genome 4Venter Institute Scientists Create First Synthetic Bacterial Genome 5Venter Institute Scientists Create First Synthetic Bacterial Genome 6Accuray Announces New Treatment Planning Service Offering 2Accuray Announces New Treatment Planning Service Offering 3Accuray Announces New Treatment Planning Service Offering 4
(Date:11/3/2009)...r more than 25 years, all attempts at culturing pe...been unsuccessfuluntil now. For the first time, no...beaded (nucleated) and non-beaded cultured pearls ...ists from Florida Atlantic University,s Harbor Bra... two years of research and experimentation, Drs. H...
(Date:11/3/2009)... and vegetables is a new, patented technology in w...d to label, or "etch" information on produce, ther...abels. The technology has been licensed for use on...sed in New Zealand, Australia, and Pacific Rim cou...frica, Central and South America, Canada, and the ...
(Date:11/3/2009)...hool of Engineering and Applied Science have for t...boratory the enzyme responsible for producing the ... , The research, published Oct. 23 in the jour...opment of other compounds with similarly beneficia...me is one of the most interesting but least unders...
Breaking Biology News(10 mins):Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 2Scientists are first to 'unlock' the mystery of creating cultured pearls from the queen conch 3Laser etching safe alternative for labeling grapefruit 2UCLA researchers reconstitute enzyme that synthesizes cholesterol drug lovastatin 2Retirement Cruise Ship Nearing Launch 50276 1Retirement Cruise Ship Nearing Launch 50276 2Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 1Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 2Baxa Corporations Dennis Tribble PharmD Now Profiled at Expert411 com for Media and Professional Access 50271 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 1BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 2BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 3BioGlue 28R 29 Surgical Adhesive Hits 500 000 Procedure Milestone Worldwide Company Data Indicates 50267 4
...have flourished ?their beauty evolving over time ?...ssociate professor of genetics at Rutgers and co-a...the whys and wherefores of flowering plants in an ...came on the scene to attract potential pollinators... that accounts for the incredible variety of shape...
...ty" and 3D reconstruction of the volcano on their...chers at Scripps Institution of Oceanography at th...red an active underwater volcano near the Samoan I...the Samoan hot spot, scientists uncovered a submar...r larger underwater volcano, Vailulu,u. Researcher...
...l, the human immunodeficiency virus hijacks that c... itself. New HIV particles roll off the cellular a... and float off to invade other cellular factories....s have now identified an early step in HIV particl...ll, could lead to new drugs that combat HIV infect...
Other Biology News:The evolutionary triumph of flower power 2Researchers discover underwater volcano 2Researchers discover underwater volcano 3Shutting down the HIV assembly line 2
...nd DNA-topoisomersae II inhibitor (IC50 = 59.2 M)....88.55658 Store at: RT CAS: 33419-42-0 S... [5R-[5alpha,5abeta,8aalpha,9beta(R*)]]-9-[(4,6-...etrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo[3...
Rabbit Anti-Human ALS2CR2 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Rabbit Anti-IKKbeta / IKK-2 Polyclonal Antibody, Unconjugated from BioVision
...vanced RACE (rapid amplification of cDNA ends) tec...full-length 5' and 3' cDNA ends. The GeneRacer Kit...ptase (RT) for improved amplification of the full-... H portion of SuperScript II RT has been inactivat...
Biology Products: